The Trump administration bought nearly the entire global supply of a new coronavirus treatment as some states reverse reopening plans over continued spread of the coronavirus.
The administration bought more than 500,000 treatment courses of remdesivir, representing all of July's production and 90% of the production for August and September. The antiviral drug is produced by Gilead Sciences.
"President Trump has struck an amazing deal to ensure Americans have access to the first authorized therapeutic for COVID-19," said HHS Secretary Alex Azar. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people."
Remdesivir is one of the only treatments so far shown to combat COVID-19, according to Reuters. It will cost $3,120 per treatment course for U.S. patients with private insurance.
Gilead Sciences is also currently developing an inhaled version of the drug for outpatient use.